Johnson & Johnson Archives - Page 12 of 33

The cloud is transforming medtech: Amazon, Microsoft, Google, J&J, Philips and GE Healthcare leaders explain

[Illustration via Adobe Stock]

Leaders in medtech and cloud computing discuss payoffs and potential in device connectivity, product development and cross-industry partnerships.

If knowledge is power, that power comes from a steady stream of information, and we know there’s no shortage of that in healthcare.

The challenge has long been how to capture that information, store it, analyze it and deploy it to improve medical product design, manufacturing and the health of patients.

Then came the cloud, and with it a host of acronyms: software as a service (SaaS), platform as a service (PaaS), infrastructure as a service (IaaS), and — following the same convention — software as a medical device (SaMD).

Over the past few months, Medical Design & Outsourcing connected with leaders in medtech and cloud computing, including the three largest providers of cloud computing services: Amazon (Nasda…

May 2022 Issue: The cloud is transforming medtech

The cloud is transforming medtech: Amazon, Microsoft, Google, J&J, Philips and GE Healthcare leaders explain

How DeepWell is developing video games as tools for treating medical conditions

Digital therapeutics open up new opportunities in medicine

Harnessing the power of cloud computing

When Johnson & Johnson and Microsoft announced a deal earlier this year to use cloud computing to support digital surgery, executives on both sides spoke with Medical Design & Outsourcing about how the partnership could advance medtech.

That started a series of conversations with leaders at cloud computing giants Google, Microsoft and Amazon — and on the device side at Johnson & Johnson, Philips and GE Healthcare. We consistently heard that the COVID-19 pandemic accelerated cloud adoption not only for medical records and telehealth, but also for manufacturing operations, supply chain management and making new vaccines, therapies and d…

Manufacturing matchmaker Fictiv raises $100M for supply chain push

Fictiv co-founder and CEO Dave Evans [Photo courtesy of Fictiv]Fictiv has closed a $100 million Series E funding round, the on-demand manufacturing technology company said today.

Fictiv focuses on “helping companies produce better products,” co-founder and CEO Dave Evans said, with three main offerings: new product development, engineer-to-order products, and maintenance, repair and operations (MRO).

But the company doesn’t actually own any manufacturing equipment, and instead has built a vetted network of 250 manufacturing partners, Evans told DeviceTalks Editorial Director Tom Salemi in an interview. After medical device developers upload their designs to Fictiv’s web-based platform, they get instant pricing and help choosing from different manufacturing methods, standards and prices to find the best fit.

Get the full story at our sister site, Medical Design & Outsourcing.

Manufacturing matchmaker Fictiv raises $100M for supply chain push

Fictiv co-founder and CEO Dave Evans [Photo courtesy of Fictiv]

Fictiv has closed a $100 million Series E funding round, the on-demand manufacturing technology company said today.

Fictiv focuses on “helping companies produce better products,” co-founder and CEO Dave Evans said, with three main offerings: new product development, engineer-to-order products, and maintenance, repair and operations (MRO).

But the company doesn’t actually own any manufacturing equipment, and instead has built a vetted network of 250 manufacturing partners, Evans told Device Talks Editorial Director Tom Salemi in an interview. After medical device developers upload their designs to Fictiv’s web-based platform, they get instant pricing and help choosing from different manufacturing methods, standards and prices to find the best fit.

“I’m the go-between [with contract manufacturers] bec…

Johnson & Johnson Vision wins Fast Company award for drug-eluting contact lens

[Image from Johnson & Johnson Vision]Johnson & Johnson Vision announced today that it was named a winner of Fast Company’s 2022 World Changing Ideas Awards.

The eye health business arm of Johnson & Johnson (NYSE: JNJ) received the award in the “Wellness” category for its Acuvue Theravision with ketotifen (etafilcon A drug-eluting contact lens with ketotifen). The drug-eluting contact, which provides a new wearing experience for contact lens wearers who have allergic eye itch for up to 12 hours without the need for allergy drops while also providing vision correction, received FDA approval in March.

Get the full story at our sister site, Drug Delivery Business News.

Why Janssen’s nipocalimab could represent a ‘pipeline in a pathway’

At the heart of Johnson & Johnson’s (NYSE:JNJ) $6.5 billion acquisition of Momenta Pharmaceuticals in 2020 is a portfolio of drug candidates for immune-mediated diseases.

One of the promising compounds in the acquisition is nipocalimab, which Janssen sees as a potential “pipeline in a pathway.” Nipocalimab holds promise for an array of diseases, ranging from rheumatoid arthritis and lupus and rare diseases such as myasthenia gravis. In all, Janssen is testing the drug in ten rare diseases as well as in rheumatoid arthritis and systemic lupus erythematosus.

When taken as a whole, rare diseases are not altogether rare, said Dr. Neely Mozaffarian, vice president and autoantibody pathway area leader at Janssen Immunology.

According to an analysis in the European Journal of Human Genetics, anywhere from 3.5% to 5.9% of the world’s population suffers from a rare disease, affecting 263–446 million people globally.

Rare autoant…

FDA clears J&J’s Ethicon’s Monarch surgical robot for urology procedures

[Image from Auris Health’s website]Johnson & Johnson MedTech (NYSE:JNJ) company Ethicon announced today that its Monarch robotic surgery platform received FDA 510(k) clearance.

Ethicon’s Auris Health subsidiary received the FDA clearance for Monarch for endourological procedures, making it the first and only multispecialty, flexible robotic solution for use in both bronchoscopy and urology.

The company said in a news release that it designed the Monarch robot-assisted surgical platform to enable urologists to reach and visualize areas within the kidney with precision and control. The system offers one platform for supporting both ureteroscopic and percutaneous nephrolithotomy (PCNL) procedures.

“Monarch reduces the complexity of gaining high-quality percutaneous access and aids stone clearance efficiency through simultaneous fragmentation and suctioning of stones with robotic assistance,” University of Southern Cali…

Johnson & Johnson shareholders approve racial justice audit proposal

Johnson & Johnson (NYSE: JNJ) investors voted in support of a proposal for a third-party racial justice audit at the annual shareholder meeting.

It was the only shareholder proposal to pass at yesterday’s annual meeting, where investors also considered proposals to discontinue global sales of baby powder containing talc, to study the public health costs of protecting COVID-19 vaccine technology, and to include legal and compliance costs in executive pay metrics.

The vote is only advisory, so it doesn’t require Johnson & Johnson to take action, but it sends a strong signal from investors that they view racial justice as a business matter.

Get the full story at our sister site, Medical Design & Outsourcing.

Johnson & Johnson shareholders approve racial justice audit proposal

Johnson & Johnson (NYSE: JNJ) investors voted in support of a proposal for a third-party racial justice audit at the annual shareholder meeting.

It was the only shareholder proposal to pass at yesterday’s annual meeting, where investors also considered proposals to discontinue global sales of baby powder containing talc, to study the public health costs of protecting COVID-19 vaccine technology, and to include legal and compliance costs in executive pay metrics.

The vote is only advisory, so it doesn’t require Johnson & Johnson to take action, but it sends a strong signal from investors that they view racial justice as a business matter.

A similar proposal in 2021 had significant support. Johnson & Johnson opposed the proposals both years, saying the company already makes diversity, equity and inclusion (DEI) part of its credo and core values.

Corporate Secretary Matthew Orlando announced the proposal’s passage at the close…

18 of the world’s most innovative medical technologies

[Images courtesy of Sysmex, Abbott, Boston Scientific, Medtronic and Siemens Healthineers]Judges this week are voting for the most innovative medical technologies among the nominees for the 2022 Prix Galien International Awards.

The Prix Galien International Awards highlight the most innovative technologies in the life sciences industry. The New York-based Galien Foundation presents the international award to eligible nominees that have received a Prix Galien award within the last two years in the Best Biotechnology Product, Best Digital Health Solution, Best Medical Technology, Best Pharmaceutical Product and Best Vaccine categories.

The Prix Galien International Awards ceremony will be co-hosted with the Prix Galien U.K. Award ceremony on May 12 at the Natural History Museum in London.

Companies included in this year’s nominees range from large multinational corporations like Medtronic to smaller medtech companies like Devices4Care. Here are the 18 medica…

Johnson & Johnson reaches opioid settlement with Alabama opioid

On the heels of announcing a $99 million opioid settlement with West Virginia, Johnson & Johnson (NYSE:JNJ) has reached a similar deal worth $77 million with the State of Alabama.

The agreement removes J&J from cases filed in the state.

The agreement did not involve an admission of liability or wrongdoing.

In January, J&J reached similar deals with Colorado and Nevada.

Alabama had a drug overdose rate of 22.3 out of 100,000 people in 2020, which is roughly average for the U.S. West Virginia, conversely, has a death rate of 81.4 out of 100,000, which is the nation’s highest.

Johnson & Johnson MedTech is shopping for M&A deals

Top officials at Johnson & Johnson (NYSE: JNJ) are eager to acquire companies with technologies that could enhance their MedTech business.

That was one of the big takeaways yesterday from the company’s earnings call. MedTech is rebounding well from the COVID-19 pandemic, with revenues up 5.9% year-over-year in the first quarter.

The company is reaching its lowest net debt levels and is looking for mergers that are a strategic fit for MedTech, CFO Joe Wolk said during the earnings call, transcribed by The Motley Fool.

“I would not get overly locked into size. … Really the outliers are these larger acquisitions. But we look at really the strategic merit and then the financial value creation and don’t get locked into saying something is too small or too big with respect to adding to our already dynamic internal portfolio and pipeline,” Wolk said.

Added MedTech’s EVP Ashley McEvoy: “We’re going to co…